Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of outcomes in patients > or =70 years versus <70 years after transradial coronary stenting with maximal antiplatelet therapy for acute coronary syndrome.
Bagur R, Bertrand OF, Rodés-Cabau J, Rinfret S, Larose E, Tizón-Marcos H, Gleeton O, Nguyen CM, Roy L, Costerousse O, De Larochellière R. Bagur R, et al. Among authors: costerousse o. Am J Cardiol. 2009 Sep 1;104(5):624-9. doi: 10.1016/j.amjcard.2009.04.050. Epub 2009 Jun 24. Am J Cardiol. 2009. PMID: 19699334 Clinical Trial.
One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) Study.
Bertrand OF, Rodés-Cabau J, Larose E, Nguyen CM, Roy L, Déry JP, Courtis J, Nault I, Poirier P, Costerousse O, De Larochellière R. Bertrand OF, et al. Among authors: costerousse o. Am Heart J. 2008 Jul;156(1):135-40. doi: 10.1016/j.ahj.2008.02.006. Epub 2008 Apr 25. Am Heart J. 2008. PMID: 18585508 Clinical Trial.
Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.
Bertrand OF, Rodés-Cabau J, Larose E, Nguyen CM, Déry JP, Proulx G, Roy L, Poirier P, Costerousse O, De Larochellière R. Bertrand OF, et al. Among authors: costerousse o. Int J Cardiol. 2009 Aug 14;136(2):165-70. doi: 10.1016/j.ijcard.2008.04.073. Epub 2008 Jul 25. Int J Cardiol. 2009. PMID: 18656274 Clinical Trial.
Early and late outcomes in patients excluded from same-day home discharge after transradial stenting and maximal antiplatelet therapy.
Bertrand OF, Rodés-Cabau J, Larose E, Proulx G, Gleeton O, Nguyen CM, Nault I, Roy L, Poirier P, Costerousse O, De Larochellière R. Bertrand OF, et al. Among authors: costerousse o. Catheter Cardiovasc Interv. 2008 Nov 1;72(5):619-25. doi: 10.1002/ccd.21662. Catheter Cardiovasc Interv. 2008. PMID: 18942124 Clinical Trial.
Impact of female gender and transradial coronary stenting with maximal antiplatelet therapy on bleeding and ischemic outcomes.
Tizón-Marcos H, Bertrand OF, Rodés-Cabau J, Larose E, Gaudreault V, Bagur R, Gleeton O, Courtis J, Roy L, Poirier P, Costerousse O, De Larochellière R. Tizón-Marcos H, et al. Among authors: costerousse o. Am Heart J. 2009 Apr;157(4):740-5. doi: 10.1016/j.ahj.2008.12.003. Epub 2009 Jan 31. Am Heart J. 2009. PMID: 19332204 Clinical Trial.
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.
Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title L, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després JP; VICTORY trial investigators. Bertrand OF, et al. Among authors: costerousse o. Can J Cardiol. 2009 Sep;25(9):509-15. doi: 10.1016/s0828-282x(09)70136-9. Can J Cardiol. 2009. PMID: 19746240 Free PMC article. Clinical Trial.
101 results